妊娠期疟疾化学预防中双氢青蒿素-哌喹与磺胺多辛-乙胺嘧啶的药物相互作用
在乌干达妊娠妇女中开展随机对照试验的药代动力学子研究,比较SP单用与DP+SP联用。强化采样显示联用使磺胺多辛和乙胺嘧啶的峰浓度、AUC及第23天浓度降低25%-34%(P<0.05),稀疏采样显示妊娠晚期 trough 浓度降低更明显。联用使哌喹AUC降低19%(P=0.046),临床后果未知。
要点
- DP+SP联用显著降低磺胺多辛和乙胺嘧啶暴露,妊娠晚期降幅大于中期。
- 联用使哌喹AUC降低19%,其他哌喹药代参数无显著差异。
- 该相互作用的临床后果尚不明确,需进一步评估。
核心结论
- DP与SP联用显著降低SP暴露,且妊娠晚期降幅大于中期,临床后果未知。
研究设计与样本
- 在乌干达妊娠妇女随机对照试验(每月IPTp:SP vs DP vs DP+SP)的子集中开展强化和稀疏药代动力学研究。
- 强化采样:87名参与者在妊娠28周给药后第0至23天采样。
- 稀疏采样:另外196名接受SP或DP+SP的参与者在妊娠20和28周给药后第28天( trough)采样。
主要发现
- 强化分析:与单用SP相比,DP+SP联用使磺胺多辛的最大浓度、AUC和第23天浓度分别降低25%、25%和27%(所有比较P<0.05)。
- 强化分析:与单用SP相比,DP+SP联用使乙胺嘧啶的最大浓度、AUC和第23天浓度分别降低26%、34%和32%(所有比较P<0.05)。
- 稀疏分析:与单用SP相比,DP+SP联用在妊娠20和28周给药后 trough 磺胺多辛浓度分别降低6%(P=0.68)和31%(P=0.023)。
- 稀疏分析:与单用SP相比,DP+SP联用在妊娠20和28周给药后 trough 乙胺嘧啶浓度分别降低18%(P=0.032)和33%(P<0.001)。
- 与单用DP相比,DP+SP联用使哌喹AUC降低19%(P=0.046),其他药代参数无显著差异。
临床怎么用
- 临床应关注DP+SP联用时SP暴露降低,尤其妊娠晚期,可能影响IPTp疗效。
局限性
- 该相互作用的临床后果尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Co-administration of dihydroartemisinin-piperaquine (DP) and sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria in pregnancy (IPTp) may be superior in preventing adverse birth outcomes compared with either therapy alone, but potential drug-drug interactions require investigation. We conducted intensive and sparse pharmacokinetic (PK) studies in a subset of Ugandan women participating in a randomized controlled trial of monthly IPTp with SP vs. DP vs. DP + SP. Intensive PK sampling was performed from day 0 to 23 after dosing at 28 weeks gestation in 87 participants across treatment arms. Sparse sampling was performed on day 28 (trough) after dosing at 20 and 28 gestational weeks in additional 196 participants receiving SP vs. DP + SP. Intensive PK analysis demonstrated that compared with SP alone, co-administration of DP + SP was associated with lower maximal concentrations, the area under the concentration-time curves (AUC), and day 23 concentrations of sulfadoxine (25%, 25%, and 27%) and pyrimethamine (26%, 34%, and 32%) (P < 0.05 for all comparisons). Sparse PK results demonstrated participants co-administered DP + SP had lower trough concentrations after dosing at 20 and 28 gestational weeks for sulfadoxine (6%, P = 0.68 and 31%, P = 0.023, respectively) and pyrimethamine (18%, P = 0.032 and 33%, P < 0.001, respectively) compared with SP alone. Co-administration of DP + SP was associated with a 19% reduction in piperaquine AUC (P = 0.046), but no significant difference in other PK parameters compared with DP alone. In summary, co-administration of DP + SP was associated with significantly reduced SP exposure, with a greater magnitude during the third vs. second trimester. The clinical consequences of this interaction are yet unknown.
引用
- Mwebaza N, Roh ME, Geng YZ, et al. Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women. Clin Pharmacol Ther. 2024. PMID: 39402742. doi:10.1002/cpt.3471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。